Natriumcromoglicaat Teva (Sodium Cromoglicate)

Sodium cromoglicate acts on ocular allergic pathways to reduce inflammation and symptom severity.

• Allergic conjunctivitis: alleviates itching, redness, and tearing associated with seasonal or perennial eye allergies.
• Prophylaxis of ocular allergic reactions: prevents onset of symptoms when patients are exposed to known allergens.
• Seasonal allergic conjunctivitis: provides pre‑emptive control of eye irritation during high pollen periods.

• Sodium cromoglicate stabilises mast cells in the conjunctival and corneal tissues, inhibiting the release of histamine, leukotrienes, and other inflammatory mediators. By preventing degranulation, it reduces vascular permeability and nerve activation, thereby limiting the ocular allergic response without directly blocking histamine receptors.

Adverse reactions are generally mild and local to the eye.

Common Side Effects

• Transient ocular burning or stinging at instillation.
• Mild blurred vision lasting a few minutes.
• Temporary tearing or watery discharge.
• Foreign‑body sensation.
• Mild headache.
• Conjunctival hyperemia.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis) with swelling of the eyelids or face.
• Corneal ulceration or epithelial defect.
• Persistent eye pain or photophobia.
• Vision loss or sudden visual acuity change.
• Severe eyelid edema.
• Acute intraocular inflammation.

Before prescribing sodium cromoglicate, clinicians should consider patient‑specific factors and handling requirements.

• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: unknown excretion in milk; assess risk versus benefit.
• Pediatric use: safety data limited; monitor closely in children.
• Contact lens wear: advise removal during treatment and for at least 15 minutes after instillation.
• Hypersensitivity: discontinue if signs of severe local or systemic allergic reaction appear.
• Store at room temperature: keep in original container, protect from light and moisture.

Sodium cromoglicate may interact with other ocular or systemic agents, requiring attention to combined effects.

Major Interactions (Avoid)

• Topical ophthalmic anesthetics: increased risk of corneal toxicity when used concurrently.
• Systemic antihistamines: may diminish the perceived efficacy of the eye drop.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: additive risk of intra‑ocular pressure elevation.
• Contact lens cleaning solutions: potential incompatibility affecting drug stability.
• Systemic immunosuppressants: monitor for heightened infection risk due to combined anti‑inflammatory actions.